← All trials
NCT05873881
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2023
- Primary completion
- Jun 30, 2027
- Completion date
- Jun 30, 2027
- First posted
- May 24, 2023
- Last posted
- Sep 26, 2023
- Enrollment
- 2500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Hamilton Health Sciences CorporationLead sponsor
- McMaster UniversityCollaborator
- McMaster UniversityOverall official - principal investigator
- Canadian Institutes of Health Research (CIHR)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.